Type 2 Biologics and Asian Chronic Rhinosinusitis
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2022.0505
- VernacularTitle:2型生物制剂和亚洲慢性鼻窦炎
- Author:
Yu-rong BAI
1
;
Ya-na ZHANG
1
Author Information
1. Department of Otolaryngology-Head and Neck Surgery， The Third Affiliated Hospital of Sun Yat-Sen University， Guangzhou 510630， China, The Third Affiliated Hospital of Sun Yat-Sen University， Guangzhou 510630， China
- Publication Type:Review
- Keywords:
Asian chronic rhinosinusitis;
biologics;
type 2 inflammation;
endotype;
treatment
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2022;43(5):720-729
- CountryChina
- Language:Chinese
-
Abstract:
Chronic rhinosinusitis （CRS） is a highly heterogeneous disease with various epidemiological and immunopathological characteristics among patients of distinct races and regions. Despite adequate and proper medical and endoscopic surgical treatment， a significant proportion of patients with CRS still experience postoperative recurrence. Difficult-to-treat severe CRS represents a number of management challenges to the practicing clinician. The advent of type 2 biologics provides a new option for the treatment of refractory and relapsed CRS. Currently， biologics targeting type 2 inflammation have been shown to be effective in improving clinical outcomes， and become a promising therapy of refractory nasal polyps in patients from western countries. However， the therapeutic effect of biologics targeting type 2 inflammation still needs to be further verified in Asian CRS patients since patients with CRS in Asia present more type 1 and type 3 inflammatory endotype as well as mixed type 2 inflammation. In addition， the development of new biologics targeting the specific endotype of Asian CRS patients will be an important research orientation in the future. In this review， we discuss the historical perspective of type 2 biologics， the inflammatory endotype characteristics of CRS in Asian， current treatment status and potential therapeutic prospects.
